Inspection Record

Bioport Corporation — FDA 483 Findings

US FDAInspected 2015-07-28Published 2024-01-17 15 findingsOther quality systemDeviation, CAPA, and investigationEquipment and facilityDocumentation and recordsLaboratory and QC controls

View the regulator's official source The source document is always the basis for judgement.

Findings

1Other quality system

The LUMAC is notperiodically reviewed for accuracy and completeness by thequality unit.

2Other quality system

The firm has not set specifications forbioburden testing though they began testing for pre-filtration bulk on 2/20/97, Organisms found include but are not limited to Bacillus species, Corynebacterium species, Pseudomonas species,Micrococcus species, and Acinetobacter species.

3Other quality system

Asmoke test was performed (and videotaped) in April 1999; however, there are no records to indicate the reason, or to provide an evaluation of its acceptability and Quality Assurance : approval.

4Deviation, CAPA, and investigation

The investigation report, approved by management 10/11/00, indicated thatafl?

5Deviation, CAPA, and investigation

The firm has not conducted an investigation as a result ofthis VAERS report, B.

6Equipment and facility

There was no preventive maintenance program, including filter inspection and replacement .

7Equipment and facility

Smoke testing was not performed in conjunction with allowable low and high air velocity range, for the HEPA filter bank.

8Other quality system

There is no mirrorin gowning room 48 to assure that employees comply with gowning procedures, .

9Other quality system

Pursuant te Section 704(b) of the Federal Food, Drug and Cosmetic a Act, or : ; .

10Documentation and records

Batch production records indicate that Witter Vials were removed during filling: ad.

11Equipment and facility

There is no assurance that environmental samples taken in the filling suite in Building@& Room @@@ and the capping area Building @} RoomQB are representative ofactual .

12Other quality system

Empty chamber cold spot heat distribution studies in 1996 indicate that protocol - | .

13Deviation, CAPA, and investigation

"Planned Deviations” allow departures.from procedures or manufacturing processes and no reports are i | |.

14Other quality system

Loaded chamber cold spot determinations have not been performed for minimum and so "maximum loads, for each vial size.

15Laboratory and QC controls

Somework orders for corréctive maintenance or repairs were marked as“Critical Systems Work Order,” SEE however, were not signed/dated as reviewed by Quality Assurance, Quality Control, Critical Systems Se Committee, or other management as required, In addition, there was no indication that product impact was ot evaluated.

About this record

Extracted automatically from the document US FDA published on 2024-01-17. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Bioport Corporation company profile — full history US FDA documents, 2024 Go to Findings search